Effects of a Dopamine Agonist on Pharmacodynamics of Levodopa in Parkinson's Disease

Completed · Phase 1

Conditions studied: Parkinson's Disease

In brief

The purpose of this study is to determine whether there is a benefit to giving a dopamine agonist to a patient with Parkinson's disease who is already being treated with levodopa.

Key facts

Study ID

NCT00666653

Run by

Oregon Health and Science University

People needed

13

Starts

2003-07-01

Expected to finish

2007-05-01

Last updated by the study team

2008-04-25

Who can join

Age: 30 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 30-80
• Idiopathic PD Hoehn \& Yahr stage 2-4,
• diagnosed by 2 of the 3 cardinal motor features
• Fluctuation response to levodopa
• Dyskinesia
• No other historical, laboratory or physical signs to suggest an alternate diagnosis
• No significant dementia, MMSE>24
• On oral levodopa therapy

You may not qualify if…

• dementia
• psychosis
• severe anxiety
• unstable cardiovascular disease
• uncontrolled hypertension
• history of cardiac arrhythmias
• active peptic ulcer disease
• anemia (HCT<32%)

Where it is running

• Oregon Health & Science University — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.